Good news - America's free trade deal with Europe is
Good news - America's free trade deal with Europe is dying
Donald Trump's near certain nomination as the Republican Party candidate for the White House could be the final nail in the coffin for President Obama's big free trade deal with Europe.
Talks on the Trans-Atlantic Trade and Investment Partnership (TTIP) began in 2013. Obama and European Union leaders hoped to create a free trade area spanning more than half of the world's economic output and 800 million people. Its supporters say the deal would make everyone richer and create lots of jobs.
But after 13 rounds of negotiations, there is growing opposition on both sides of the Atlantic. The odds of a deal happening any time soon have collapsed.
Here are three reasons why:
1 . Trump hates it , Clinton is cooling fast
During the primaries, Trump has repeatedly criticized free trade agreements, including NAFTA and the Trans-Pacific Partnership, saying they are "an attack on America's business."
"TTIP is being used as a political tool and it works...blaming foreigners for problems in the economy," said Dennis Novy, an international trade expert and an associate professor of economics at the University of Warwick.
Related: The war on business during presidential campaign
Hillary Clinton, frontrunner to win the Democratic nomination for president, backed big free trade agreements when she was Secretary of State. But she is now also voicing concerns. In October, she spoke out against the Trans-Pacific Partnership, a trade deal between the U.S. and 11 other nations.
"The debate has pushed Clinton into being much more skeptical," said Raoul Ruparel, a co-director of Open Europe, a think tank. "It looks like this (trade agreement) may not be a top priority for whoever comes in after the election."
2. Growing opposition in Europe
Nearly 3.5 million Europeans have signed a petition against the deal. They are worried it would give too much power to big U.S. corporations, and make it easier for them to bypass environmental and public health protection laws.
"There is a lot of underlying anti-American sentiment in Europe, especially against big American corporations, on environmental issues, labor issues, tax issues," Novy said.
Related: Slowing world trade is bad news for the economy
The French government said this week it won't sign TTIP in its current form. Trade Minister Matthias Fekl reportedly said that Europe was getting a bad deal and it would be better to put the talks on hold if the U.S. wasn't prepared to give more ground.
Opponents in Europe say the agreement could lead to privatization of healthcare, education and transport, sectors run as public services in many European countries. The European Commission says these sectors will not be included in the agreement, but leaks suggest the U.S. is pushing hard for access.
Protesters are also furious about the secrecy surrounding the negotiation. The draft deal has been kept under wraps -- which is not unusual for big trade agreements. WikiLeaks has offered a reward worth 100,000 euros ($114,000) for the TTIP documents.
3. Time is running out
Time is fast running out to negotiate the big thorny issues. Both sides are playing hardball, trying to defend their interests.
"Even though they say they want a 'win-win' agreement, what they actually mean is 'we want to win more than you do,'" said Julius Sen, an associate director at The International Trade Policy Unit at the London School of Economics.
Related: Why Europeans hate Obama's free trade deal
Talks began in June 2013 and the negotiators originally hoped for a deal before Obama leaves office in January. But that looks very unlikely now.
"Nobody really believes it will be done," Sen said. "It is not possible to negotiate and implement an agreement like this within the life cycle of one congress, one president, it will move very slowly," he added.
A British parliamentary report published this week showed international trade deals take between four and nine years on average to negotiate.
1
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...
Continue Reading
Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...
Continue Reading
Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...
Continue Reading
A fish, a kilowatt-hour, a microchip, and a shipping container walk into the same economic story—well, not literally, thank goodness—and that is the unusual wager behind CCTV4’s upcoming Our Home, Our Yangtze. Announced in Beijing on November 19, 2026, the four-part documentary aims to recount a decade of change across the Yangtze River Economic Belt without leaning...
Continue Reading
A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...
Continue Reading
Personalized cancer vaccines have no shortage of grand promises; seasoned clinical operators are the rarer commodity. That is why BreakBio's appointment of Dr. Greg Lizée as chief scientific officer deserves a closer look, even if nobody should confuse an executive hire with clinical validation. BreakBio is private, its lead program remains in development, and cancer...
Continue Reading
Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...
Continue Reading
Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...
Continue Reading
Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...
Continue Reading
A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...
Continue Reading
Top 5 Most Recently Viewed Articles
Eagle Pharmaceuticals Board Extends Rights Plan Duration Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) has announced an update regarding its stockholder rights plan. The Board of Directors has approved an important amendment to the existing limited duration rights plan, extending its validity for one additional year, until October 30, 2026. Reason for the Amendment This...
Continue Reading
Trump's Immigration Policies and Economic Growth Donald Trump's approach to immigration is likely to influence the rate of migration into the United States significantly, implying a potential slowdown in the nation's economic growth. Analysts at Piper Sandler have expressed concerns that the upcoming policies could lead to a meaningful deceleration in migration rates that...
Continue Reading
Sonder Holdings Faces Nasdaq Compliance Challenges Sonder Holdings Inc. (NASDAQ: SOND), a cutting-edge hospitality company known for its tech-enhanced accommodations, recently received a formal notification from Nasdaq regarding a compliance issue. This is primarily due to the company's delay in filing its Q3 financial report for the period ending September 30, 2024. The...
Continue Reading
Overview of the 2024 AvaSure Symposium Healthcare professionals from across the country are preparing to convene for the 2024 AvaSure Symposium. This event will focus on the significant impact of AI-driven virtual care platforms on improving patient outcomes, enhancing staff satisfaction, and ensuring a healthy return on investment (ROI). Event Information The upcoming...
Continue Reading
Revolutionizing Scientific Communication: Stempad's Winter Update Stempad, the world's first alternative for pen-and-paper scientific writing, has excited the academic community with the announcement of its new winter features. This innovative tool supports students, educators, and researchers in STEM fields, ensuring they have a seamless solution for effective scientific...
Continue Reading